News Releases

News Category

Year

10 Sep '2021

Advaxis Reports 3rd Quarter Ended July 31, 2021 Financial Results and Provides a Business Update

Entered definitive merger agreement with Biosight Ltd. to advance pipeline of clinical-stage oncology programs for solid tumors and hematological malignancies Initiated Phase 1 clinical trial of ADXS-504 for the treatment of early prostate cancer ADXS-503 Phase 1/2 data presented at ASCO

PDF Version

16 Aug '2021

Biosight Announces Initiation of Investigator Sponsored Phase 2 Clinical Trial of Aspacytarabine for Relapsed/Refractory AML and MDS with the Groupe Francophone des Myélodysplasies

First Patient Enrolled to the Phase 2 Trial, which will Evaluate Single-Agent Aspacytarabine in Second Line Relapsed/Refractory AML and MDS Study sponsored by Groupe Francophone des Myélodysplasies, the French Study Group of the European Myelodysplastic Syndromes Cooperative Group AIRPORT CITY,

PDF Version

11 Aug '2021

Nasdaq Grants Advaxis, Inc. an Extension to November 22, 2021, to Regain Compliance with the $1.00 Minimum Bid Price Rule and Complete Merger Transaction with Biosight, Ltd.

MONMOUTH JUNCTION, N.J. , Aug. 11, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS) (“Advaxis” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of proprietary Lm-based antigen delivery products, announced that it has received a letter

PDF Version

15 Jul '2021

Advaxis Announces Initiation of Phase 1 Clinical Trial of ADXS-504 for the Treatment of Early Prostate Cancer

Study in biochemically recurrent prostate cancer expands off-the-shelf ADXS-HOT program to second indication MONMOUTH JUNCTION, N.J. , July 15, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of

PDF Version

14 Jul '2021

Advaxis to Present at the Non-Small Cell Lung Cancer Drug Development Summit

PRINCETON, N.J. , July 14, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS ), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that Andres Gutierrez , M.D., Executive Vice President and Chief Medical Officer of

PDF Version

06 Jul '2021

Advaxis and Biosight Announce Entry into Definitive Merger Agreement

– Combined Company Will Operate as Biosight Therapeutics to Advance Pipeline of Clinical-Stage Oncology Programs with Lead Program Aspacytarabine (BST-236) in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) – Combined Company Will be Well-Funded with Cash Position of approx.

PDF Version

14 Jun '2021

Advaxis Reports Second Quarter Ended April 30, 2021 Financial Results and Provides a Business Update

ADXS-503 Phase 1/2 trial data presented at ASCO demonstrate disease control rate of 44% with durable clinical benefit observed beyond one year in patients with disease progression on KEYTRUDA ® Expansion of off-the-shelf ADXS-HOT program with planned Phase 1 study in early prostate cancer with

PDF Version

19 May '2021

Advaxis Presents Updated Clinical Data from Ongoing Phase 1/2 Trial of ADXS-503 in NSCLC at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting

Updated data show disease control rate of 44% with durable clinical benefit observed beyond one year in patients with disease progression on pembrolizumab Translational data support potential of ADXS-503 to restore and/or enhance sensitivity to checkpoint inhibitors PRINCETON, N.J.

PDF Version

28 Apr '2021

Advaxis to Present at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting

PRINCETON, N.J. , April 28, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS ), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that will present data from Part B of the Phase 1 study of ADXS-503 in combination

PDF Version

26 Apr '2021

UPDATE - Advaxis Announces Achievement of Second Milestone Under ADXS-HER2 Licensing Agreement with OS Therapies

Non-dilutive capital will support advancement of ADXS-HOT neoantigen program PRINCETON, N.J. , April 26, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that

PDF Version

Pagination

Current page 1
Page 2
Next page
Last page

Displaying 1 - 10 of 19